glp 1 shortage ending Compounding pharmacies to halt semaglutide sales May 22 GLP-1 Antagonists Increase Plan Drug

A new paper published by pharmacist and PSM board member Dr

At the average 231-lb starting weight used in Phase 2 trials, a 24.2% weight loss equals approximately 56 lbs

Summary Keywords endocrinology, growth hormone secretagogues, IGF-1 analogues, off-label use, peptide hormones, performance-enhancing drugs, sports doping Citation Dominikowski A, Rko Z, Olejarz M, Szczepanek-Parulska E, Domin R and Ruchaa M (2026) The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

FDA guidance for industry combined with initial FDA feedback specific to the pivotal Phase 3 program of avexitide for PBH suggest that reduction in hypoglycemia events could be an endpoint to support approval following positive results from a pivotal Phase 3 clinical trial